Advertisement

Loading...

PolyNovo Limited

PNV.AXASX
Healthcare
Medical - Devices
$0.94
$0.010(1.07%)
Australian Market opens in 17h 57m

PolyNovo Limited Fundamental Analysis

PolyNovo Limited (PNV.AX) shows moderate financial fundamentals with a PE ratio of 69.92, profit margin of 7.16%, and ROE of 11.87%. The company generates $0.1B in annual revenue with strong year-over-year growth of 23.31%.

Key Strengths

PEG Ratio-2.78
Current Ratio3.03

Areas of Concern

Operating Margin1.98%
Cash Position4.24%
We analyze PNV.AX's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 63.4/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.

Fundamental Health Score

C+
63.4/100

We analyze PNV.AX's fundamental strength across five key dimensions:

Efficiency Score

Weak

PNV.AX struggles to generate sufficient returns from assets.

ROA > 10%
8.01%

Valuation Score

Moderate

PNV.AX shows balanced valuation metrics.

PE < 25
69.92
PEG Ratio < 2
-2.78

Growth Score

Moderate

PNV.AX shows steady but slowing expansion.

Revenue Growth > 5%
23.31%
EPS Growth > 10%
1.51%

Financial Health Score

Excellent

PNV.AX maintains a strong and stable balance sheet.

Debt/Equity < 1
0.38
Current Ratio > 1
3.03

Profitability Score

Weak

PNV.AX struggles to sustain strong margins.

ROE > 15%
11.87%
Net Margin ≥ 15%
7.16%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is PNV.AX Expensive or Cheap?

P/E Ratio

PNV.AX trades at 69.92 times earnings. This suggests a premium valuation.

69.92

PEG Ratio

When adjusting for growth, PNV.AX's PEG of -2.78 indicates potential undervaluation.

-2.78

Price to Book

The market values PolyNovo Limited at 8.31 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

8.31

EV/EBITDA

Enterprise value stands at 96.66 times EBITDA. This signals the market has high growth expectations.

96.66

How Well Does PNV.AX Make Money?

Net Profit Margin

For every $100 in sales, PolyNovo Limited keeps $7.16 as profit after all expenses.

7.16%

Operating Margin

Core operations generate 1.98 in profit for every $100 in revenue, before interest and taxes.

1.98%

ROE

Management delivers $11.87 in profit for every $100 of shareholder equity.

11.87%

ROA

PolyNovo Limited generates $8.01 in profit for every $100 in assets, demonstrating efficient asset deployment.

8.01%

Following the Money - Real Cash Generation

Operating Cash Flow

PolyNovo Limited produces operating cash flow of $24.95M, showing steady but balanced cash generation.

$24.95M

Free Cash Flow

PolyNovo Limited produces free cash flow of $5.37M, offering steady but limited capital for shareholder returns and expansion.

$5.37M

FCF Per Share

Each share generates $0.01 in free cash annually.

$0.01

FCF Yield

PNV.AX converts 0.78% of its market value into free cash.

0.78%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

69.92

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-2.78

vs 25 benchmark

P/B Ratio

Price to book value ratio

8.31

vs 25 benchmark

P/S Ratio

Price to sales ratio

5.009

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.38

vs 25 benchmark

Current Ratio

Current assets to current liabilities

3.03

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.12

vs 25 benchmark

ROA

Return on assets percentage

0.08

vs 25 benchmark

ROCE

Return on capital employed

0.03

vs 25 benchmark

How PNV.AX Stacks Against Its Sector Peers

MetricPNV.AX ValueSector AveragePerformance
P/E Ratio69.9228.31 Worse (Expensive)
ROE11.87%699.00% Weak
Net Margin7.16%-130884.00% (disorted) Weak
Debt/Equity0.380.34 Neutral
Current Ratio3.032775.16 Strong Liquidity
ROA8.01%-14469.00% (disorted) Weak

PNV.AX outperforms its industry in 1 out of 6 key metrics, but lagging in P/E Ratio.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews PolyNovo Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

449.67%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

401.55%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

848.44%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ